Abdulla A. Damluji, MD, PhD Profile picture
Nov 5, 2021 20 tweets 18 min read Read on X
Cardiac Arrest and Cardiogenic Shock

There is a societal paper on this in the works too!

Very important work!

@Babar_Basir @venumenon10

#TCT2021 @TCTMD
Methylprednisone - ? not helpful

Advanced reperfusion strategies - small trial

#TCT2021
SCAI Shock Classification

Milrinone vs Dobutamine - no difference

Gaps in pressers in CICU setting: pressers and antiplatelets

@seanvandiepen @JasonKatzMD

#TCT2021
Invasive hemodynamics monitoring

MCS

Unloading

#TCT2021
Shock Teams - CICU @JACCJournals

3-axis model

HF readmission in shock pt

Excellent @Babar_Basir

#TCT2021

@SandeepNathanMD excellent session
***Multi-vessel PCI in Shock***

First side of the coin

Multivessel PCI should not be performed in shock ??

Culprit Shock: Culprit only

NNT = 12

@thiele_holger

#TCT2021
European guidelines

Long term outcomes

STEM pts?
Culprit lesion only PCI and followed by stage PCI in shock
Multivessel PCI in Shock is Way to Go

ESC Guidelines

CI cross in culprit cross at one year?

Metaanalysis - may be there is benefit?

But there is increased risk in renal failure

Culprit is open label - procedural differences?

@BillONeillMD

#TCT2021
NCSI -

77% improved outcomes with support

Culprit vs NCSI

#TCT2021
Conclusion - too nuanced to tell?

#TCT2021
Decisions to use what device in cardiogenic shock

@SandeepNathanMD
Trials and registry data

Impella vs balloon pump
Impella CP in AMI Shock?

#TCT2021
The Pro Case?

Impella CP as first line in shock

Goal in AMI Shock - improved supply/demand

Hemodynamic Effect of IABP, pLVAD, and ECMO

#TCT2021
IABP in AMI-CS

The longer patients linger? the more likely they die...@behnam_tehrani

#TCT2021
Impella Data

Reducing cardiac work

NCSI data @Babar_Basir
Shock teams in patients from the critical care cardiology network @ShashankSinhaMD
Escalation of Device Therapies

- ECMO + Impella (facilitating LV recovery?)

All good, but we need clinical trials in this space.

So far it is hard to argue with @SandeepNathanMD
Excellent session and great speakers @BinitaShahMD @NavinKapur4

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Dec 18
Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations: @Sciencedirect

🥸 This is a new manuscript from our team ~ led by @MichaelGNanna on ALL lipid lowering therapy and cognitive function.

😱 Very nicely done by @heartwiselab team.

🥸Here is a summary

👇👇👇Image
🥸1️⃣ Lipid-lowering therapy is a cornerstone of cardiovascular risk reduction in older adults. However, concerns about possible cognitive side effects, especially in the setting of aggressive low-density lipoprotein cholesterol reduction, persist among patients and clinicians.
🥸2️⃣ Statins have been the primary focus of this concern. While early case reports described memory loss and attention deficits, subsequent systematic evaluations have found no consistent evidence that statins impair cognition in older adults.
Read 22 tweets
Nov 21
Social Determinants of Cardiovascular Aging: @JACCJournals

🥸 Great work led by Aaron Troy on social determinants of an aging population.

😱 Summary below

👇👇👇👇 Image
🥸1️⃣Social and economic conditions shape cardiovascular aging as strongly as traditional risk factors. These exposures begin early, accumulate over decades, and alter vascular, myocardial, valvular, and electrophysiologic aging trajectories.
🥸2️⃣Cardiovascular aging follows distinct paths depending on structural determinants such as race, gender, education, and geography. These determinants influence baseline risk, access to care, biologic stress, and clinical expression of disease.
Read 21 tweets
Oct 1
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology: @JACCJournals and @ACCinTouch

🥸 Inflammation and aging are interlinked: #inflammaging

😱 Great science statement here

👇👇👇 Image
🥸 1️⃣ Inflammation and cardiovascular disease frames risk beyond cholesterol; residual inflammatory risk by hsCRP often persists despite statins, so a patient with LDL at goal but hsCRP 3–5 mg/L still faces higher event rates and needs a plan that targets inflammation directly.
🥸 2️⃣ hsCRP behaves like blood pressure or LDL in risk tools; use <1, 1–3, >3 mg/L as low, intermediate, high relative risk, and repeat any value >10 mg/L after infections settle so you act on a stable baseline rather than a transient spike.
Read 21 tweets
Sep 7
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis: @TheLancet

🥸Plavix for secondary prevention may be superior to aspirin

😱 Summary

👇👇👇 Image
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸2️⃣ However, multiple randomized trials have recently compared clopidogrel directly with aspirin as a single-agent strategy. This 2025 meta-analysis provides the most comprehensive assessment to date by combining patient-level data.
Read 21 tweets
Sep 3
Global Uptake of GLP-1 Receptor Agonists in Obese, Non-Diabetic Patients with Cardiovascular Disease: @ESC_Journals

🥸New publication from our @heartwiselab research group: @MichaelGNanna

😱Older adults use: 1.9% of semaglutide and 1.3% of tirzepatide - summary

👇👇👇 Image
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸2️⃣ SELECT enrolled 17,604 adults ≥45 years with overweight or obesity (BMI ≥27) and prior MI, stroke, or PAD, but no diabetes. Semaglutide led to a 20% relative risk reduction in major adverse cardiovascular events.
Read 21 tweets
Aug 30
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias: @NEJM

🥸 The statement: "Keep K above 4 and Mg above 2" still holds: #ESCCongress2025

😱 Summary

👇👇👇 Image
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸2️⃣ It was a randomized, multicenter trial in Denmark enrolling 1,200 patients with potassium ≤4.3 mmol/L and an implantable cardioverter-defibrillator for primary or secondary prevention.
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(